回购日期回购均价回购股数回购金额本年累计回购股数2025-08-0511.0318.40万92.66万982.90万2025-07- 0410.30220.00万206.03万974.50万2025-06-2710.04020.00万200.80万954.50万2025-06-2010.24010.00万 102.40万934.50万2025-06-179.91645.00万446.20万924.50万2025-06-1310.23210.00万102.32万879.50万 2025-06-1210.23510.00万102.35万869.50万2025-06-059.15870.00万641.06万859.50万2025-05-238.52630.00 万255.78万789.50万2025-05-228.72750.00万436.35万759.50万2025-05-198.23915.00万123.58万709.50万 2025-05-168.23910.00万82.39万694.50万2025-05-147.94234.70万275.60万684.50万2025-05-127.22380.00万 577 ...

智通财经APP讯，和誉-B(02256)发布公告，于2025年8月5日斥资92.66万港元回购股份8.4万股，每股回 购价格为10.82-11.35港元。 ...

和誉-B(02256)发布公告，于2025年8月5日斥资92.66万港元回购股份8.4万股，每股回购价格为10.82- 11.35港元。 ...

格隆汇8月5日丨和誉-B(02256.HK)公告，8月5日耗资92.7万港元回购8.4万股。 ...

Core Viewpoint - The company, He Yu-B (02256), experienced a significant stock price increase of over 10% following the release of its interim financial results, indicating strong market confidence in its performance and future prospects [1] Financial Performance - For the six months ending June 30, 2025, the company reported revenue of RMB 612 million, representing a year-on-year increase of 23.1% [1] - Research and development expenses amounted to RMB 228 million, up 6.02% year-on-year, attributed to the advancement of pipeline projects [1] - Adjusted profit for the period reached RMB 336 million, reflecting a substantial year-on-year growth of 56.03% [1] - Net profit was reported at RMB 328 million, marking a year-on-year increase of 58.84% [1] Share Buyback and Market Confidence - The board approved a share buyback program with a maximum allocation of HKD 200 million aimed at boosting market confidence and enhancing shareholder value [1] - As of June 30, 2025, the company repurchased 9.545 million shares, which is 1.4% of the total shares issued as of January 1, 2025, at a total cost of HKD 75.3 million [1] - In 2024, the company also repurchased a total of 22.594 million shares for a cumulative amount of HKD 68.7 million [1] - The founder, chairman, and CEO, Dr. Xu Yaochang, demonstrated confidence in the company's business outlook by purchasing an additional 132,000 ordinary shares in the open market during the first half of the year [1]

Group 1 - Xindong Company (02400) reported a positive earnings forecast, expecting revenue of at least RMB 3.05 billion for the first half of 2025, a year-on-year increase of approximately 37%, and a net profit of at least RMB 790 million, a year-on-year increase of about 215% [1] - Yimai Sunshine (02522) also announced a positive earnings forecast, expecting revenue between RMB 450 million to 480 million for the first half of the year, a year-on-year increase of approximately 8.77% to 16.03%, and a net profit of RMB 14.5 million to 16.5 million, a year-on-year increase of about 1350% to 1550% [1] - Tianli International Holdings (01773) plans to repurchase shares up to a total of HKD 200 million based on market conditions, believing that the share buyback plan is in the best interest of the company and its shareholders [2] Group 2 - Liaogang Co., Ltd. (02880) reported a total operating revenue of RMB 5.693 billion for the first half of 2025, a year-on-year increase of 5.93%, and a net profit attributable to shareholders of RMB 956 million, a year-on-year increase of 110.78% [2] - Yuan Zheng Technology (02488) reported a revenue of RMB 982 million for the first half of 2025, a year-on-year increase of 9.75%, and a net profit of RMB 195 million, a year-on-year increase of 27.74% [2] - Geekplus Technology (02590) expects revenue between RMB 995 million to 1.03 billion for the first half of the year, a year-on-year increase of 27% to 32%, while the net loss is expected to narrow significantly [3] Group 3 - Lee & Man Paper Manufacturing (02314) and other leading companies in the paper industry have initiated a price increase for various products starting August 1, indicating a significant acceleration in price adjustment frequency within the industry [3] - Xinda Biopharmaceutical (01801) announced that its innovative oral small molecule GLP-1R agonist IBI3032 has received IND approval from the FDA [4] - Heyu-B (02256) reported a revenue of RMB 612 million for the first half of the year, a year-on-year increase of 23.1%, and a net profit of RMB 328 million, a year-on-year increase of 58.84% [4] Group 4 - Bilibili (BILI.US) is expected to achieve a revenue growth of 20% year-on-year to RMB 7.3 billion in the second quarter, driven by stable performance in mobile games [5][6] - Li Auto (LI.US) launched the Li Xiang i8, with deliveries starting on August 20, and received positive outlooks from multiple institutions [6] - Xpeng Motors (XPEV.US) achieved a new monthly delivery record in July, delivering 36,717 smart electric vehicles, a year-on-year increase of 229% [7]

Group 1 - The core viewpoint of the articles highlights the strong performance of He Yu-B (02256), a research-driven biopharmaceutical company focused on innovative drug development for small molecule precision oncology and immunotherapy, with a notable stock price increase of 6.7% on August 5 [1][3] - He Yu-B has five projects currently in clinical stages, aiming to address unmet needs of cancer patients globally through differentiated therapies supported by a robust R&D platform and team [1] - For the fiscal year 2025 mid-term report, He Yu-B reported total revenue of 612 million RMB and a net profit of 328 million RMB, with a year-on-year increase in attributable profit to shareholders of 58.84%, resulting in basic earnings per share of 0.53 RMB [2]

值得注意的是，和誉近日宣布，其研发的新型PRMT5*MTA抑制剂ABSK131，已在针对MTAP缺失的晚 期/转移性实体瘤患者的1期临床试验中完成首例患者给药。据悉，2024年12月，ABSK131获得美国食品 药品监督管理局的IND批准。2025年3月，ABSK131获中国国家药品监督管理局药品审评中心的IND批 准。 消息面上，和誉发布业绩，上半年收入6.12亿元人民币，同比增加23.1%；期内经调整利润3.36亿元， 同比增加56.03%；净利润3.28亿元，同比增加58.84%。公告称，收入主要为来自默克的授权收入。此 外，公司购回股份以提振市场信心及提升股东价值。截至2025年6月30日止6个月，公司共购回954.5万 股股份，累计金额7530万港元。于2024年，亦合计购回2259.4万股股份，累计金额6870万港元。 和誉-B(02256)绩后涨近7%，截至发稿，涨4.02%，报10.87港元，成交额1.46亿港元。 ...

Core Viewpoint - The company, He Yu-B (02256), experienced a nearly 7% increase in stock price following the release of its financial results, reflecting positive market sentiment driven by strong revenue and profit growth [1] Financial Performance - For the first half of the year, the company reported revenue of 612 million RMB, representing a year-on-year increase of 23.1% [1] - Adjusted profit for the period was 336 million RMB, up 56.03% year-on-year [1] - Net profit reached 328 million RMB, marking a 58.84% increase compared to the previous year [1] Share Buyback - The company has engaged in share buybacks to boost market confidence and enhance shareholder value, repurchasing a total of 9.545 million shares for 75.3 million HKD in the six months ending June 30, 2025 [1] - In 2024, the company repurchased an additional 22.594 million shares for a total of 68.7 million HKD [1] Research and Development - He Yu-B announced the completion of the first patient dosing in a Phase 1 clinical trial for its new PRMT5*MTA inhibitor, ABSK131, targeting late-stage/metastatic solid tumor patients with MTAP deletion [1] - The company received IND approval from the U.S. FDA for ABSK131 in December 2024 and from the China National Medical Products Administration in March 2025 [1]

今年7月29日，和誉-B(02256)盘中最高股价达到11.74港元，创下公司近4年以来的股价新高，而这也让和誉年初至今的股价最大涨幅达到155.22%。 在高涨的股价让二级市场投资者投资回报水涨船高的同时，和誉也在持续通过注销式股票回购方式用"真金白银"回馈投资者。今年3月，和誉董事会再次批 准了公司动用2亿港元在市场上购回股份，截至今年6月30日，公司已累计回购954.50万股，合计7530万港元。 实际上，今年以来，港股创新药板块走出了一波大爆发行情。而从和誉最新披露的2025年中期财报投资者不难看出，随着创新研发与国际化BD预期的不断 兑现，公司顺利实现了持续性规模化的创新收益与盈利，并产生了丰富的现金流，为公司中长期创新研发提供了可观的资金保障，也进一步完善了公司"创 新-盈利"的正循环。今年上半年不断攀升的股价反映的便是市场对公司价值的高度认可。 规模化盈利预期获持续兑现 今年上半年，和誉得以实现规模化盈利预期的持续兑现，其中的关键载体便是商业化价值持续释放的核心品种匹米替尼。 作为首个中国自主研发进入全球III期TGCT临床试验的CSF-1R抑制剂，匹米替尼目前已获中美欧多国监管机构突破性疗法认 ...